We have recently found that the chronic subcutaneous administration of EGF to mice during the development of myelin ODC-specific-glycoprotein(MOG)-induced EAE prevents the onset of the disease and improves the clinical condition and SC histopathology (Nicoletti et al. 2019); furthermore, it has been shown that EGF administration is effective in inducing the CNS remyelination in two other models of chemically-induced CNS demyelination, i.e. lysolecithin-induced and cuprizone-induced CNS demyelination (see Table 5B). This evidence concerns the gene EGF and CNS demyelination.